Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 11 | 2011 | 390 | 1.110 |
Why?
|
| Medicaid | 4 | 2011 | 254 | 0.710 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 130 | 0.620 |
Why?
|
| Psychotic Disorders | 6 | 2010 | 150 | 0.560 |
Why?
|
| Anticonvulsants | 2 | 2006 | 396 | 0.400 |
Why?
|
| Polypharmacy | 1 | 2011 | 41 | 0.360 |
Why?
|
| Neoplasms | 3 | 2020 | 3036 | 0.330 |
Why?
|
| Platelet Aggregation | 2 | 2000 | 125 | 0.310 |
Why?
|
| Candidiasis | 2 | 2007 | 138 | 0.300 |
Why?
|
| Financing, Personal | 1 | 2008 | 10 | 0.300 |
Why?
|
| Medicare Part D | 1 | 2008 | 17 | 0.300 |
Why?
|
| Sodium-Hydrogen Exchangers | 2 | 1999 | 41 | 0.290 |
Why?
|
| Drug Therapy | 1 | 2008 | 94 | 0.290 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1183 | 0.290 |
Why?
|
| Antimanic Agents | 1 | 2007 | 37 | 0.270 |
Why?
|
| Fluconazole | 1 | 2007 | 50 | 0.270 |
Why?
|
| Hepatitis A Vaccines | 1 | 2006 | 10 | 0.260 |
Why?
|
| Mental Disorders | 2 | 2011 | 890 | 0.260 |
Why?
|
| Hepatitis B Vaccines | 1 | 2006 | 45 | 0.260 |
Why?
|
| Nitric Oxide | 2 | 2000 | 487 | 0.250 |
Why?
|
| Aged | 24 | 2020 | 21822 | 0.250 |
Why?
|
| United States | 20 | 2020 | 11798 | 0.250 |
Why?
|
| Health Resources | 1 | 2007 | 127 | 0.250 |
Why?
|
| Hospitalization | 6 | 2011 | 1919 | 0.240 |
Why?
|
| Incidence | 8 | 2020 | 3424 | 0.240 |
Why?
|
| Schizophrenia | 2 | 2008 | 332 | 0.230 |
Why?
|
| SEER Program | 4 | 2019 | 224 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2007 | 541 | 0.210 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 327 | 0.210 |
Why?
|
| Calcium | 2 | 1999 | 1148 | 0.210 |
Why?
|
| Drug Utilization | 4 | 2010 | 170 | 0.200 |
Why?
|
| Lung | 2 | 2021 | 1578 | 0.200 |
Why?
|
| Computer Simulation | 3 | 2014 | 709 | 0.190 |
Why?
|
| Logistic Models | 7 | 2010 | 1909 | 0.190 |
Why?
|
| Dementia | 5 | 2010 | 489 | 0.190 |
Why?
|
| Middle Aged | 17 | 2020 | 29430 | 0.180 |
Why?
|
| Thrombin | 2 | 1999 | 63 | 0.180 |
Why?
|
| Vaccination | 1 | 2006 | 1019 | 0.180 |
Why?
|
| Adult | 14 | 2020 | 31962 | 0.180 |
Why?
|
| Azores | 1 | 2020 | 2 | 0.170 |
Why?
|
| Portugal | 1 | 2020 | 9 | 0.170 |
Why?
|
| Models, Statistical | 3 | 2019 | 507 | 0.170 |
Why?
|
| Models, Genetic | 2 | 2014 | 790 | 0.170 |
Why?
|
| Aged, 80 and over | 11 | 2014 | 7244 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 158 | 0.170 |
Why?
|
| Male | 26 | 2021 | 66215 | 0.160 |
Why?
|
| Nursing Homes | 3 | 2010 | 107 | 0.160 |
Why?
|
| Endothelium, Vascular | 2 | 2000 | 524 | 0.160 |
Why?
|
| Female | 27 | 2021 | 72054 | 0.160 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 15 | 0.160 |
Why?
|
| Lipoproteins, HDL | 1 | 2000 | 118 | 0.160 |
Why?
|
| Prostatic Neoplasms | 3 | 2019 | 1626 | 0.160 |
Why?
|
| Adolescent | 10 | 2021 | 20647 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2020 | 277 | 0.160 |
Why?
|
| Software | 2 | 2014 | 736 | 0.150 |
Why?
|
| Prevalence | 4 | 2011 | 2685 | 0.150 |
Why?
|
| Retrospective Studies | 14 | 2011 | 17591 | 0.140 |
Why?
|
| Colon | 1 | 2020 | 380 | 0.140 |
Why?
|
| Humans | 32 | 2021 | 134225 | 0.140 |
Why?
|
| Young Adult | 6 | 2020 | 9963 | 0.140 |
Why?
|
| Child, Preschool | 7 | 2021 | 14897 | 0.140 |
Why?
|
| Organoids | 1 | 2020 | 300 | 0.140 |
Why?
|
| Infant | 6 | 2021 | 13263 | 0.130 |
Why?
|
| Drug Prescriptions | 2 | 2011 | 243 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 419 | 0.130 |
Why?
|
| Forecasting | 1 | 2018 | 377 | 0.130 |
Why?
|
| Georgia | 2 | 2006 | 39 | 0.120 |
Why?
|
| Infant, Newborn | 5 | 2021 | 8640 | 0.120 |
Why?
|
| Stem Cells | 1 | 2021 | 754 | 0.120 |
Why?
|
| Age Factors | 5 | 2011 | 2997 | 0.120 |
Why?
|
| United States Food and Drug Administration | 3 | 2020 | 159 | 0.120 |
Why?
|
| Blood Platelets | 1 | 1998 | 342 | 0.120 |
Why?
|
| Child | 8 | 2021 | 25917 | 0.110 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 262 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2020 | 825 | 0.110 |
Why?
|
| Risk | 4 | 2011 | 833 | 0.110 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 8 | 0.110 |
Why?
|
| Rabbits | 3 | 2000 | 726 | 0.110 |
Why?
|
| Health Care Surveys | 3 | 2009 | 294 | 0.100 |
Why?
|
| Cross-Sectional Studies | 6 | 2011 | 3759 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 652 | 0.100 |
Why?
|
| Prescriptions | 2 | 2009 | 43 | 0.090 |
Why?
|
| Residence Characteristics | 3 | 2008 | 293 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 920 | 0.090 |
Why?
|
| Losartan | 1 | 2011 | 36 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 63 | 0.090 |
Why?
|
| Tetrazoles | 1 | 2011 | 64 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 116 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 1493 | 0.090 |
Why?
|
| Time Factors | 3 | 2011 | 6595 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2010 | 432 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 239 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2011 | 136 | 0.080 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 138 | 0.080 |
Why?
|
| Off-Label Use | 1 | 2010 | 28 | 0.080 |
Why?
|
| Homes for the Aged | 1 | 2010 | 26 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 38 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 226 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 124 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2011 | 5225 | 0.080 |
Why?
|
| Hematinics | 1 | 2010 | 60 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2010 | 120 | 0.080 |
Why?
|
| Drug Utilization Review | 1 | 2009 | 33 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 27 | 0.070 |
Why?
|
| Sexual Behavior | 1 | 2010 | 251 | 0.070 |
Why?
|
| Military Personnel | 1 | 2010 | 204 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 211 | 0.070 |
Why?
|
| Cattle | 2 | 2000 | 589 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 563 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2010 | 1512 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2020 | 986 | 0.070 |
Why?
|
| Heart Failure | 2 | 2011 | 2440 | 0.070 |
Why?
|
| Risk Factors | 6 | 2021 | 11196 | 0.070 |
Why?
|
| Lithium Compounds | 1 | 2007 | 16 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2007 | 48 | 0.070 |
Why?
|
| Drug Resistance, Fungal | 1 | 2007 | 30 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2007 | 73 | 0.070 |
Why?
|
| Hepatitis A | 1 | 2006 | 32 | 0.070 |
Why?
|
| Lymphoma | 1 | 2010 | 334 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2007 | 168 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2007 | 117 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2006 | 30 | 0.060 |
Why?
|
| Emergency Service, Hospital | 3 | 2010 | 1166 | 0.060 |
Why?
|
| Affect | 1 | 2007 | 172 | 0.060 |
Why?
|
| Anemia | 1 | 2010 | 351 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 401 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 682 | 0.060 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2006 | 98 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 288 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2011 | 13105 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2006 | 173 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 129 | 0.060 |
Why?
|
| Survivors | 1 | 2007 | 358 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2007 | 305 | 0.060 |
Why?
|
| Depression | 2 | 2010 | 1365 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 906 | 0.050 |
Why?
|
| Vancomycin | 1 | 2006 | 236 | 0.050 |
Why?
|
| Urban Population | 1 | 2005 | 244 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 273 | 0.050 |
Why?
|
| Algorithms | 2 | 2010 | 1739 | 0.050 |
Why?
|
| Cross Infection | 1 | 2006 | 344 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1735 | 0.050 |
Why?
|
| Bacteremia | 1 | 2006 | 429 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 874 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2171 | 0.050 |
Why?
|
| Length of Stay | 1 | 2007 | 1392 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 2093 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 45 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2020 | 61 | 0.040 |
Why?
|
| Viral Tropism | 1 | 2020 | 53 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2021 | 87 | 0.040 |
Why?
|
| Immune System | 1 | 2021 | 98 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 201 | 0.040 |
Why?
|
| Cohort Effect | 1 | 2019 | 5 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1999 | 11 | 0.040 |
Why?
|
| Propensity Score | 2 | 2011 | 263 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 177 | 0.040 |
Why?
|
| Nigericin | 1 | 1998 | 3 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1998 | 24 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 1999 | 197 | 0.040 |
Why?
|
| HIV Infections | 1 | 2010 | 2073 | 0.040 |
Why?
|
| Biological Transport, Active | 1 | 1998 | 89 | 0.040 |
Why?
|
| Animals | 4 | 2020 | 36526 | 0.030 |
Why?
|
| Anxiety | 3 | 2009 | 1004 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1163 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 356 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1303 | 0.030 |
Why?
|
| Kidney Pelvis | 1 | 2017 | 46 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 1486 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1999 | 292 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 105 | 0.030 |
Why?
|
| Aorta | 1 | 2000 | 562 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 81 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 112 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2011 | 1260 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 121 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 36 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 1999 | 544 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2592 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 271 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2000 | 3181 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 266 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 445 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 440 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 315 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 462 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 723 | 0.020 |
Why?
|
| Models, Structural | 1 | 2011 | 50 | 0.020 |
Why?
|
| Valsartan | 1 | 2011 | 23 | 0.020 |
Why?
|
| Fosinopril | 1 | 2011 | 3 | 0.020 |
Why?
|
| Lisinopril | 1 | 2011 | 23 | 0.020 |
Why?
|
| Enalapril | 1 | 2011 | 14 | 0.020 |
Why?
|
| Captopril | 1 | 2011 | 27 | 0.020 |
Why?
|
| Nigeria | 1 | 2010 | 81 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 51 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 739 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 8 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2010 | 87 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2010 | 4008 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 105 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 404 | 0.020 |
Why?
|
| Texas | 2 | 2010 | 3719 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 207 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 710 | 0.020 |
Why?
|
| Social Class | 1 | 2010 | 210 | 0.020 |
Why?
|
| Veterans | 2 | 2011 | 1788 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 428 | 0.020 |
Why?
|
| Social Behavior | 1 | 2010 | 230 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 399 | 0.020 |
Why?
|
| Quetiapine Fumarate | 1 | 2008 | 17 | 0.020 |
Why?
|
| Dibenzothiazepines | 1 | 2008 | 15 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 24 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 3056 | 0.020 |
Why?
|
| Health Policy | 1 | 2010 | 233 | 0.020 |
Why?
|
| Risperidone | 1 | 2008 | 60 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2008 | 112 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2006 | 24 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1251 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2006 | 113 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1783 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 1416 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1595 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 1350 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1388 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 614 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 753 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2011 | 804 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 2265 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2006 | 1338 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 19049 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3678 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2006 | 407 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3119 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 5466 | 0.010 |
Why?
|
| Quality of Life | 1 | 2010 | 2163 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1854 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 6617 | 0.010 |
Why?
|